In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $61.68, with a -1.03% movement compared to the previous day. The stock's performance was behind the S&P 500's daily loss of 0.13%.

Viking Therapeutics, Inc.'s stock surged 1,500% on the promising obesity drug VK-2735, with Phase 3 trials and potential for ...

We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Viking ...

Viking Therapeutics VKTX has outperformed the market over the past 5 years by 41.66% on an annualized basis producing an ...

I'm bullish on Viking Therapeutics' weight-loss drug, but warn of risks and competition ahead. Click here to read my most ...

Viking Therapeutics (NASDAQ: VKTX) has captured the attention of investors, with its stock price skyrocketing over 400% in ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Investors with a lot of money to spend have taken a bearish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Viking Therapeutics Inc. (NASDAQ: VKTX), a clinical-stage biotechnology company with a market cap approaching $7 billion, is ...

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $70.47 which represents a slight increase of $2.31 or 3.39% from the prior close of $68.16. The stock opened at $69.5 and ...

While it might not perfectly follow in the larger biotech's footsteps, TERN-601 has the potential to be one of the safer, ...